Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 443

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 443
---
 loss is minimal as the cash is held by large, highly-rated
financial institutions. 

F-8

Research and Development Tax Incentive Receivable

The Company, through its wholly-owned subsidiary
in Australia, participates in the Australian research and development tax incentive program, such that a percentage of our qualifying
research and development expenditures are reimbursed by the Australian government, and such incentives are reflected as a reduction of
research and development expense. The Australian research and development tax incentive is recognized when there is reasonable assurance
that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured.
At each period end, management estimates the reimbursement available to the Company based on available information at the time.

The Company, through its wholly-owned subsidiary
in the United Kingdom, participates in the research and development program provided by the United Kingdom tax relief program, such that
a percentage of our qualifying research and development expenditures are reimbursed by the United Kingdom government, and such incentives
are reflected as a reduction of research and development expense. The United Kingdom research and development tax incentive is recognized
when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the
consideration can be reliably measured. At each period end, management estimates the reimbursement available to the Company based on available
information at the time.

Intangible Assets

The Company capitalizes costs incurred in connection
with in-process research and development purchased from others if the asset has alternative uses and such uses are not restricted under
applicable license agreements; patent applications (principally legal fees), patent purchases, and trademarks related to its cell line
as intangible assets. Acquired in-process research and development costs that do not have alternative uses are expensed as incurred. When
the assets are determined to have a finite life (upon completion of the development of the in-process research and development for its
DN-TNF platform), the useful life will be determined, and the in-process research and development intangible assets will be amortized.

During the fourth quarter and if business factors
indicate more frequently, the Company performs an assessment of the qualitative factors affecting the fair value of our in-process research
and development. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.
The quantitative analysis involves a comparison of the fair value of the in-process research and development with the carrying amount.
If the carrying amount of the in-process research and development exceeds its fair